Reported Thursday, Roche's Genentech Halts SKYSCRAPER-06 Trial After Tiragolumab Plus Tecentriq And Chemotherapy Show Reduced Efficacy Compared To Comparator Arm
Portfolio Pulse from Benzinga Newsdesk
Roche's Genentech has halted the SKYSCRAPER-06 trial after the combination of tiragolumab, Tecentriq, and chemotherapy showed reduced efficacy compared to the comparator arm. The trial did not meet the primary endpoints of progression-free survival and overall survival.
July 05, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Roche's Genentech has halted the SKYSCRAPER-06 trial due to reduced efficacy of tiragolumab plus Tecentriq and chemotherapy. The trial did not meet primary endpoints, impacting Roche's oncology pipeline.
The halting of the SKYSCRAPER-06 trial due to reduced efficacy of the drug combination is a setback for Roche's oncology pipeline. This could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100